U.S. markets closed
  • S&P 500

    3,768.47
    -51.25 (-1.34%)
     
  • Dow 30

    30,924.14
    -345.95 (-1.11%)
     
  • Nasdaq

    12,723.47
    -274.28 (-2.11%)
     
  • Russell 2000

    2,146.92
    -60.87 (-2.76%)
     
  • Crude Oil

    64.03
    +2.75 (+4.49%)
     
  • Gold

    1,694.90
    -5.80 (-0.34%)
     
  • Silver

    25.37
    -0.09 (-0.36%)
     
  • EUR/USD

    1.1976
    -0.0091 (-0.75%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • GBP/USD

    1.3892
    -0.0061 (-0.44%)
     
  • USD/JPY

    107.9800
    +0.9780 (+0.91%)
     
  • BTC-USD

    48,329.51
    -2,646.08 (-5.19%)
     
  • CMC Crypto 200

    968.73
    -18.48 (-1.87%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March 31, 2020.

“During the first quarter, we sustained strong momentum on our UBX0101 development program,” said Anirvan Ghosh, chief executive officer of UNITY. “We completed enrollment of both our Phase 2 and Phase 1b studies in patients with osteoarthritis (OA) of the knee. This progress is particularly noteworthy given the impact of the COVID-19 pandemic on the clinical trial landscape.”

Recent Highlights and Business Updates

Osteoarthritis – UBX0101

In February 2020, UNITY announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe OA of the knee. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses (0.5 mg, 2.0 mg and 4.0 mg) of UBX0101 administered via a single intra-articular injection. Consistent with prior guidance, both 12- and 24-week results are expected in the second half of 2020.

In March 2020, UNITY announced completion of enrollment of a Phase 1b study of UBX010 in patients with moderate-to-severe OA of the knee. The study is randomized, double-blind, and placebo-controlled and will explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses (two 4.0 mg doses separated by one month) of UBX0101. Consistent with prior guidance, both 12- and 24-week results are expected in the second half of 2020.

Ophthalmology

UNITY is advancing its lead ophthalmology candidates, UBX1967 and UBX1325, through the final stages of Investigational New Drug (IND) -enabling studies. Both senolytic molecules are inhibitors of particular members of the Bcl-2 family of apoptosis regulatory proteins which have shown distinct pharmacokinetic profiles in preclinical studies. Consistent with prior guidance, UNITY continues to expect to file an IND for a Phase 1 safety study for this program in the second half of 2020 and, assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients, to initiate a Phase 1 study in the second half of 2020 and receive initial results from the study in 2021. However the impact of the COVID-19 pandemic is hard to assess due the rapidly evolving nature of the situation and it is possible that the study start could be delayed. The overall clinical program is directed at multiple age-related diseases of the eye, such as age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

Impact of COVID-19 Pandemic

UNITY’s first priority during the COVID-19 pandemic has been to ensure the health and safety of employees and patients in its clinical programs as well as the integrity of the studies in which they participate. UNITY’s clinical and regulatory teams remain active and are working closely with its investigators in its ongoing clinical studies of UBX0101 to adapt to the current environment and ensure the studies remain on-track. UNITY is also following FDA guidance on clinical trial conduct during the COVID-19 pandemic, including with respect to the remote monitoring of clinical data. Further, UNITY has sufficient supply of UBX0101 for all ongoing clinical studies.

In late February 2020, UNITY created a cross-functional COVID-19 Response Team to closely monitor the evolving situation and advise on UNITY’s response. In mid-March 2020, in alignment with public health guidance designed to slow the spread of COVID-19, UNITY implemented a reduced onsite staffing model and transitioned to a remote work plan for all employees other than those providing essential services, such as laboratory staff. For its onsite employees, UNITY implemented heightened safety measures designed to comply with applicable federal, state and local guidelines in response to the COVID-19 pandemic. All other employees continue to perform business activities from remote locations.

Financial Outlook

UNITY believes that current cash, cash equivalents and investments are sufficient to fund operations into the second half of 2021.

First Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $109.2 million as of March 31, 2020 compared with $125.0 million as of December 31, 2019.

Operating loss for the three months ended March 31, 2020 was $27.2 million compared to $19.7 million for the three months ended March 31, 2019. Cash used in operations during the first quarter of 2020 was $25.1 million compared to $20.6 million for the first quarter of 2019.

Research and development expenses increased by $2.8 million, to $19.3 million for the three months ended March 31, 2020 from $16.5 million for the three months ended March 31, 2019. The increase was primarily due to increases of $1.5 million in clinical study costs driven by development costs associated with UBX0101, $1.4 million in facilities-related costs, and $0.6 million in personnel-related costs, of which $0.5 million was related to non-cash stock compensation expense, partially offset by a decrease of $0.6 million in laboratory supplies.

General and administrative expenses increased by $1.5 million, to $6.0 million for the three months ended March 31, 2020 from $4.5 million for the three months ended March 31, 2019. The increase was primarily due to increases of $0.9 million in personnel-related costs, of which $0.8 million was related to non-cash stock compensation expense, $0.3 million in facilities-related costs and $0.2 million in professional fees.

About UNITY

UNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to the potential for UNITY to develop therapeutics to extend healthspan, statements related to the timing of certain regulatory filings and the release of clinical trial data and the extent to which COVID-19 may impact UNITY’s operations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 7, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.


Unity Biotechnology, Inc.
Condensed Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)

Three Months Ended

March 31,

2020

2019

Operating expenses:

Research and development

$

19,265

$

16,505

General and administrative

5,953

4,477

Change in fair value of contingent consideration

(221

)

(1,245

)

Impairment of long-lived assets

2,159

Total operating expenses

27,156

19,737

Loss from operations

(27,156

)

(19,737

)

Interest income

527

1,006

Other expense, net

(1,409

)

(36

)

Net loss

(28,038

)

(18,767

)

Other comprehensive loss

Unrealized gain on marketable securities, net of tax

283

114

Comprehensive loss

$

(27,755

)

$

(18,653

)

Net loss per share, basic and diluted

$

(0.59

)

$

(0.44

)

Weighted-average number of shares used in
computing net loss per share, basic and
diluted

47,544,401

42,190,457


Unity Biotechnology, Inc.
Condensed Balance Sheets
(In thousands)

March 31,

December 31,

2020

2019

(Unaudited)

Assets

Current Assets:

Cash and cash equivalents

$

25,059

$

37,473

Short-term marketable securities

84,179

84,508

Strategic investment

4,120

5,507

Prepaid expenses and other current assets

1,875

1,999

Total current assets

115,233

129,487

Property and equipment, net

15,067

16,636

Operating lease right of use asset

25,443

Long-term marketable securities

3,025

Restricted cash

1,446

1,446

Other long-term assets

598

627

Total assets

$

157,787

$

151,221

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

4,015

$

5,185

Accrued compensation

2,222

5,905

Accrued and other current liabilities

7,422

4,995

Contingent consideration liability

910

1,131

Total current liabilities

14,569

17,216

Operating lease liability, net of current portion

37,889

Deferred rent, net of current portion

13,298

Total liabilities

52,458

30,514

Commitments and contingencies

Stockholders' equity:

Common stock

5

5

Additional paid-in capital

379,072

366,695

Related party promissory notes for purchase
of common stock

(210

)

(210

)

Employee promissory notes for purchase
of common stock

(418

)

(418

)

Accumulated other comprehensive loss

373

90

Accumulated deficit

(273,493

)

(245,455

)

Total stockholders' equity

105,329

120,707

Total liabilities and stockholders' equity

$

157,787

$

151,221

Investors
Endurance Advisors
Peter Rahmer
prahmer@enduranceadvisors.com

Media
Canale Communications
Jason Spark
jason@canalecomm.com